6 completed, 3 not yet recruiting, 3 recruiting. 12 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 12 | Completed 6, Not yet recruiting 3, Recruiting 3 |
Follow Respiratory Syncytial Virus (RSV): new trials by email Literature Review of Respiratory Syncytial Virus (RSV) trials Research Report on Respiratory Syncytial Virus (RSV)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate Efficacy, Immunogenicity and Safety of a Recombinant Respiratory Syncytial Virus Vaccine in Older Adults Aged 60 Years and Older LYB005, Placebo - Respiratory Syncytial Virus (RSV), Respiratory Syncytial Virus (RSV) Infection | Phase 3 | Not yet recruiting | Guangzhou Patronus Biotech Co., Ltd. | 25000 | 2026-11-01 | 2026-11-02 |
| A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Older Adults RSVpreF (Regimen A), RSVpreF (Regimen B) - Respiratory Syncytial Virus (RSV) | Phase 3 | Not yet recruiting | Pfizer | 750 | 2026-10-29 | 2026-10-21 |
| Study to Learn About a Respiratory Syncytial Virus Vaccine in Children at High Risk of RSV Disease RSVpreF, Placebo - Respiratory Syncytial Virus (RSV) | Phase 3 | Not yet recruiting | Pfizer | 920 | 2026-09-28 | 2026-09-24 |
| A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults RSVpreF Vaccine - Respiratory Syncytial Virus (RSV) | Phase 3 | Recruiting | Pfizer | 440 | 2026-08-31 | 2026-10-14 |
| A Phase 3 Study in India to Describe the Safety and Immunogenicity of RSVpreF RSVpreF, Placebo - Respiratory Syncytial Virus (RSV) | Phase 3 | Recruiting | Pfizer | 540 | 2026-06-22 | 2026-09-24 |
| A Study to Learn Safety and Immune Response to Study Vaccine -RSVpreF in Adults at High Risk of Severe RSV Disease. RSVpreF - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | Pfizer | 130 | 2026-05-11 | 2026-09-24 |
| Phase III Clinical Trial of the Recombinant Respiratory Syncytial Virus Vaccine ( CHO Cell) Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell), Placebo (Saline solution) - Respiratory Syncytial Virus (RSV) | Phase 3 | Recruiting | MAXVAX Biotechnology Limited Liability Company | 25000 | 2025-10-22 | 2025-12-09 |
| A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE, HZ/su VACCINE - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | Pfizer | 526 | 2025-04-04 | 2025-11-06 |
| A Study to Assess Safety, Tolerability and Immunogenicity of RSVpreF From Multidose Vials in Healthy Female Adults. RSVpreF MDV, RSVpreF SDV - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | Pfizer | 453 | 2024-06-24 | 2025-09-25 |
| A Study to Assess the Safety, Tolerability, and Immunogenicity of RSVpreF in Adults at High Risk of Severe RSV Disease RSVpreF, Placebo - RESPIRATORY SYNCYTIAL VIRUS (RSV) | Phase 3 | Completed | Pfizer | 885 | 2023-05-11 | 2025-08-08 |
| A Study to Assess the Safety and Effectiveness of Palivizumab Administered to Children at High Risk of Severe Respiratory Syncytial Virus (RSV) Infection in the Russian Federation and the Republic of Belarus Palivizumab - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | AbbVie | 50 | 2016-11-09 | 2018-03-13 |
| A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults RSV-F Vaccine, Phosphate Buffer Placebo - Respiratory Syncytial Virus (RSV) | Phase 3 | Completed | Novavax | 11850 | 2015-11-01 | 2022-07-19 |
Bronchopulmonary Dysplasia (1) · Congenital chloride diarrhea (1) · Infections (1) · Respiratory Syncytial Virus Infections (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Infant, Newborn, Diseases (1) · Infant, Premature, Diseases (1) · Infections (1) · Lung Diseases (1) · Lung Injury (1) · Mononegavirales Infections (1) · Paramyxoviridae Infections (1) · Pneumovirus Infections (1) · RNA Virus Infections (1) · Respiratory Tract Diseases (1) · Ventilator-Induced Lung Injury (1) · Virus Diseases (1)
Palivizumab (1) · Regimen B (1) · Saline Solution (1) · abrysvo (1)
Pfizer (8) · AbbVie (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · MAXVAX Biotechnology Limited Liability Company (1) · Novavax (1)
United States (6) · China (2) · Japan (2) · India (1) · Puerto Rico (1)
Joaquin Valdes (1) · Yanxia Wang (1)
PMID 39523547, PMID 40266222, PMID 41660362
2016 (1)